RADX
Radiopharm Theranostics Ltd
$4.21
-2.55%
$53.7M
No data for this timeframe.
Vol
Market Cap$53.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders1 funds
Inst. Value$100.4K
Inst. Activity1 buys / 0 sells
Press Releases2
Recent Activity
Inst.
UBS Group AG — NEW
17,740 shares ($82.3K)
Apr 23, 2026
other
Radiopharm Theranostics Reports Business Update
<p align="center"><em>Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in pat
Apr 8, 2026
Press
Radiopharm Theranostics announced a positive safety review by the Data Safety and Monitoring Committee, allowing advance
Impact 7/10
Mar 27, 2026
Press
Radiopharm Theranostics has dosed the first patient in a Phase 1 trial of RAD 402, a first-in-class radiolabeled monoclo
Impact 5/10
Price Targets
$17.12
+302.9% upside
Strong Buy
Current $4.25
Low $12.73
Median $15.43
High $30.27
6 analysts
$12.73
$30.27
Analyst Ratings
1Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 4, 2026 | HC Wainwright & Co. | INITIATE | Buy |
| Dec 16, 2025 | B. Riley Securities | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $-3.29 | $-3.47 — $-3.10 | 38% YoY | 2 |
| Next FY | $-3.66 | $-3.66 — $-3.66 | -11% YoY | 1 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| UBS Group AG | $100.4K | NEW |
1 institutional holders with $100.4K total value (18,191 shares) as of 2025-Q3. Top holders: UBS.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 18,191 | $100.4K | 100.0% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | NEW | — | 17,740 | — | $82.3K | 2025-Q2 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
Current analyst consensus: Strong Buy (83% buy). Based on 6 analysts: 1 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$17.12 mean target
+302.9% upside
Strong Buy (1.20)
$12.73 Low
$30.27 High
| Metric | Value |
|---|---|
| Current Price | $4.25 |
| Target Low | $12.73 |
| Target Mean | $17.12 |
| Target Median | $15.43 |
| Target High | $30.27 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.20) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-06-30 |
$-3.29 | $-3.47 | $-3.10 | 37.8% | +0.0% | — | $0.0B | -69.6% | 2 |
| Next FY 2027-06-30 |
$-3.66 | $-3.66 | $-3.66 | -11.4% | +0.0% | — | $0.0B | 306.7% | 1 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 4, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
| Dec 16, 2025 | B. Riley Securities | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| May 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Apr 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Mar 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Feb 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Jan 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 23, 2026
other
Radiopharm Theranostics Reports Business Update
<p align="center"><em>Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following ea
Apr 16, 2026
other
Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases
<p align="center"><em>Interim data to date showed 90% concordance with MRI (the primary endpoint)</em></p>
Apr 8, 2026
fda
Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to progress Phase 1 to the next dose level of 130mCi in patients wit
Apr 7, 2026
other
Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
<p align="center"><em>Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, wi
Mar 27, 2026
fda
Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
<p align="center"><em>On track to share data from first two dose levels in 2H 2026</em></p>
Mar 25, 2026
short_interest
FTD: RADX — 126,578 shares ($0.5M) failed to deliver
Settlement: 20260325, Price: $4.14, FTD Value: $524,032.92, RADIOPHARM THERANOSTICS LTD